Effect of Safinamide on Parkinson's Disease Related Chronic Pain
Idiopathic Parkinson Disease
About this trial
This is an interventional treatment trial for Idiopathic Parkinson Disease focused on measuring Parkinson disease, Safinamide
Eligibility Criteria
Inclusion Criteria:
- Participant must be 30 years of age or older, at the time of signing the informed consent.
- Diagnosed with IPD by using the United Kingdom Parkinson's Disease Society Brain Bank criteria for more than 5 years duration.
- Receiving treatment with a stable dose of oral L-Dopa (including controlled release [CR], immediate release [IR] or a combination of CR/IR), with and without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor and may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine for at least 4 weeks prior to the randomisation (baseline visit).
- Hoehn and Yahr stage between 2-3 (inclusive) during the "ON" phase at the screening visit.
- Experiencing motor fluctuations following optimum titration of treatment medications and within the 4 weeks immediately prior to randomisation.
- Experiencing chronic pain (i.e. ongoing for ≥3 months prior to screening visit); the Investigator must consider chronic pain directly related to PD and not explained by any other health problem (e.g. peripheral neuropathy, organ disease or arthritis pain) OR consider the intensity of chronic pain specifically aggravated by PD.
- If taking regular analgesics, the treatment regimen should be stable in the 4 weeks prior to the randomisation visitt.
- Able to maintain an accurate and complete electronic diary with the help of a caregiver.
Male or female
•A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: i.Not a woman of childbearing potential (WOCBP) OR ii.A WOCBP who agrees to follow the contraceptive guidance
- Capable of giving signed informed consent
Exclusion Criteria:
- Any form of Parkinsonism other than IPD.
- Diagnosis of chronic migraine (>15 days per month) or cancer pain.
- History of bipolar disorder, depression, schizophrenia or other psychotic disorder requiring treatment with neuroleptics.
- History of dementia or cognitive dysfunction.
- Severe, peak dose or biphasic dyskinesia.
- Unpredictable or widely swinging fluctuations.
- Ophthalmologic history including any of the following conditions: albinism, uveitis, retinitis pigmentosa, retinal degeneration, active retinopathy, severe progressive diabetic retinopathy, inherited retinopathy or family history of hereditary retinal disease.
- Moderate or severe liver failure using the Child-Pugh classification score.
- History of drug and/or alcohol abuse within 12 months prior to screening as defined by the current edition of the Diagnostic and Statistical Manual of Mental Disorders.
- Allergy/sensitivity, intolerance or contraindications to Safinamide.
- Treatment with monoamine oxidase inhibitors (MAOIs), levodopa infusion, pethidine, fluoxetine, fluvoxamine less than 4 weeks prior to the randomisation visit
- Use of any investigational drug or device within 30 days prior to screening or 5 half-lives, whichever is the longest
- Previous treatment with Safinamide in the 9 months before the screening visit
- Mini-Mental State Exam (MMSE) total score <24 at screening.
- NRS score ≤ 4 points at randomization visit.
- Any clinically significant condition which, in the opinion of the Investigator, would not be compatible with study participation or represent a risk for participants while in the study
Sites / Locations
- Medizinische Universitat Innsbruck
- Institut für Neuroimmunologische und Neurodegenerative Erkrankungen
- Hopital Gabriel Montpied
- CHU de GRENOBLE
- Hopitaux de La Timone
- Centre Hospitalier Universitaire de Nimes
- Hopital de Hautepierre
- Hôpital Pierre-Paul Riquet
- St. Joseph Krankenhaus Berlin
- Universitätsklinikum Carl Gustav Carus an der TU Dresden
- Katholische Kliniken Ruhrhalbinsel GmbH
- Neurologische Praxis
- University Medicine Göttingen Germany
- Klinik Haag i. OB
- Universitätsklinikum Gießen und Marburg GmbH
- Universitätsklinikum Münster
- NeuroPoint Akademie
- Universitätsklinikum Ulm
- Zambon Investigative Site
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
- Centro per la Malattia di Parkinson e i Disturbi del Movimento
- Ospedale San Raffaele S.r.l. - PPDS
- Azienda Ospedaliera Di Perugia
- Azienda Ospedaliero Universitaria Pisana
- Istituto Neurologico Mediterraneo Neuromed
- Fondazione PTV Policlinico Tor Vergata
- Ospedale San Giovanni Battista - ACISMOM
- IRCCS San Raffaele Pisana
- Azienda Ospedaliera Universitaria OO.RR. San Giovanni di Dio Ruggi d'Aragona
- Hospital del Mar
- Hospital de La Santa Creu i Sant Pau
- Hospital Universitario Vall d'Hebrón - PPDS
- C.A.U de Burgos - Hospital Universitario de Burgos
- Hospital Puerta del Mar
- Hospital Universitario de Donostia
- Hospital Universitario de La Princesa
- Hospital Universitario La Paz - PPDS
- Hospital Universitario Puerta de Hierro - Majadahonda
- Hospital HM Puerta del Sur
- Clinica Universidad Navarra
- Complejo Hospitalario de Navarra
- Hospital Universitario Virgen Macarena
- Hospital Universitario Virgen del Rocio
- Hospital Universitari i Politecnic La Fe de Valencia
- Hospital Universitario Miguel Servet
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Experimental
Placebo
Safinamide methanesulfonate film coated tablets once daily, 50 mg and 100 mg. Safinamide methanesulfonate 50 mg and 100 mg tablets was administered orally, OD, with or without food, at breakfast time when the subject was taking their morning dose of L-DOPA. Subjects received study drug 50 mg (from Day 1 to Day 7) and then 100 mg (from Day 8 onwards). The dose of 100 mg/day (titrated from 50 mg/day after 1 week) was selected based on the results of previous studies in patients with PD and from the results of a post hoc analysis that investigated the effects of safinamide on pain.
Safinamide methanesulfonate matching placebo film coated tablets once daily. The matching placebo was administered orally, OD, in tablets, with or without food, at breakfast time when the subject was taking their morning dose of L-DOPA.